scispace - formally typeset
D

Daniela Matarrese

Publications -  16
Citations -  718

Daniela Matarrese is an academic researcher. The author has contributed to research in topics: Medicine & Diabetes mellitus. The author has an hindex of 6, co-authored 15 publications receiving 485 citations.

Papers
More filters
Journal ArticleDOI

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.

TL;DR: Graphical abstract Image, graphical abstract images showing how the model transformed from a discrete-time model to a 3D model with real-time consequences has changed over time.
Journal ArticleDOI

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

TL;DR: It is found that baricitinib exerts activity rapidly through the inhibition of host proteins (numb-associated kinases), uniquely among antivirals, and is associated with beneficial outcomes including in severely ill elderly patients, data that incentivize further randomized controlled trials.
Journal ArticleDOI

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.

TL;DR: Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry and reduces COVID-19 mortality rate in a retrospective multicenter study and reduces intensive care unit admissions of CO VID-19 pneumonia.
Journal ArticleDOI

In Hospital and 3-Month Mortality and Functional Recovery Rate in Patients Treated for Hip Fracture by a Multidisciplinary Team.

TL;DR: Identification and stabilization of concomitant clinical problems by internal medicine specialists may safely decrease time to surgery in frail subjects with hip fracture and integrate perioperative clinical management may shorten hospital stay with no apparent increase in in-hospital mortality and ultimately improve the outcome.
Journal ArticleDOI

Impact of Chronic Care Model on diabetes care in Tuscany: a controlled before-after study

TL;DR: The first year of the CCM implementation had a significant impact on the diabetes care indicator, and performance was stabilized after the first year, while impact on therapy indicator was smaller.